In the phase 1/2 clinical study B7461001 (NCT01970865), lorlatinib demonstrated clinically meaningful benefit in patients with advanced non-small cell lung cancer (NSCLC), including those with intracranial metastases after progression on second-generation ALK inhibitors, and also had a favourable safety and tolerability profile [2, 3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.